Pfizer Inc
13F holdings for Q2 2026 · New York, NY · filed August 13, 2026
Pfizer Inc reported $170M in 13F securities across 17 holdings for Q2 2026, in a Form 13F filed August 13, 2026. The largest positions were ALLO (27.5%), CELC (17.3%), ARVN (16.2%). Reported value fell 28.7% from the quarter before. It opened 0 new positions, added to 0, trimmed 3 and sold out of 1.
- 13F value Q2 2026
- $170M
- Holdings
- 17
- Change vs prior quarter
- -28.7%
- Rank by 13F value
- #7,013
Holdings as of June 30, 2026, the end of Q2 2026. Managers have 45 days after a quarter ends to file Form 13F (by August 14, 2026 for Q2 2026), so positions may have changed since.
Top holdings
| Stock | Value | Weight | Shares | Change in shares | Move |
|---|---|---|---|---|---|
| ALLO Allogene Therapeutics Inc. | $46.9M | 27.5% | 22,032,040 | 0% | Unchanged |
| CELC Celcuity Inc. | $29.6M | 17.3% | 295,652 | 0% | Unchanged |
| ARVN Arvinas Inc. | $27.7M | 16.2% | 3,457,815 | 0% | Unchanged |
| PYXS Pyxis Oncology Inc. | $19.5M | 11.4% | 7,032,770 | 0% | Unchanged |
| Wave Life Sciences LTD SHS | $10.9M | 6.4% | 1,875,000 | 0% | Unchanged |
| Biohaven LTD | $8.0M | 4.7% | 505,645 | 0% | Unchanged |
| CRBU Caribou Biosciences Inc. | $7.9M | 4.6% | 4,690,431 | 0% | Unchanged |
| SPRO Spero Therapeutics Inc. | $5.3M | 3.1% | 2,362,348 | 0% | Unchanged |
| ZNTL Zentalis Pharmaceuticals Inc. | $3.9M | 2.3% | 953,834 | 0% | Unchanged |
| ORIC Oric Pharmaceuticals Inc. | $3.6M | 2.1% | 372,904 | -92.2% | Trimmed |
| CRDF Cardiff Oncology Inc. | $3.0M | 1.8% | 2,411,575 | 0% | Unchanged |
| Zura Bio LTD | $2.9M | 1.7% | 538,841 | -81.0% | Trimmed |
| AGMB AgomAb Therapeutics NV | $1.0M | 0.6% | 75,000 | 0% | Unchanged |
| BOLT Bolt Biotherapeutics Inc. | $134K | 0.1% | 31,305 | 0% | Unchanged |
| NXTC NextCure Inc. | $73K | 0.0% | 44,347 | -71.1% | Trimmed |
| DNA Ginkgo Bioworks Holdings Inc. | $30K | 0.0% | 2,928 | 0% | Unchanged |
| Senseonics Hldgs Inc | $12K | 0.0% | 2,171 | 0% | Unchanged |
Share positions only, at the value reported for the end of Q2 2026. Weight is the share of $170M in share positions; options and bonds count in the 13F value but not here.
Biggest buys in Q2 2026
None this quarter.
Biggest sells in Q2 2026
- ORIC Oric Pharmaceuticals Inc. Trimmed-$42.0M
- Zura Bio LTD Trimmed-$12.3M
- QTTB Q32 Bio Inc. Sold out-$737K
- NXTC NextCure Inc. Trimmed-$179K
The change in shares since Q1 2026, adjusted for stock splits and priced at the Q2 2026 value per share. 0 new, 0 added, 3 trimmed, 1 sold out.
Sector mix
- Health Care87.2%
- Not listed with us12.8%
13F value by quarter
Questions about Pfizer Inc
- What does Pfizer Inc own?
- In its Form 13F for Q2 2026, Pfizer Inc reported 17 holdings worth $170M. The five largest were ALLO, CELC, ARVN, PYXS, Wave Life Sciences LTD SHS.
- What did Pfizer Inc buy and sell in Q2 2026?
- Pfizer Inc opened 0 new positions, added to 0, trimmed 3 and sold out of 1 compared with the quarter before.
- When did Pfizer Inc file its latest 13F?
- Form 13F is due 45 days after each quarter ends. The Q2 2026 report was due August 14, 2026 and was filed August 13, 2026.
From Form 13F filed by Pfizer Inc (SEC CIK 0000078003) for the quarter ended June 30, 2026, via the SEC's Form 13F data sets. Amendments that restate a report replace it; amendments that add holdings are included. View on SEC EDGAR · All funds